Please use this identifier to cite or link to this item:
Title: Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model
Author: Laquente, Berta
Lacasa Salavert, Cristina
Ginestà, Mireia M.
Casanovas i Casanovas, Oriol
Figueras i Amat, Agnès
Galán, Maica
García Ribas, Ignacio
Germà Lluch, José Ramón
Capellá, G. (Gabriel)
Viñals Canals, Francesc
Keywords: Medicaments antineoplàstics
Quimioteràpia del càncer
Càncer de pàncrees
Antineoplastic agents
Cancer chemotherapy
Pancreas cancer
Issue Date: Mar-2008
Publisher: American Association for Cancer Research
Abstract: Gemcitabine shows a marked antitumor effect as a result of its cytotoxic action toward proliferative cells. In this article, we aim to investigate the potential antitumor and antiangiogenic effect of gemcitabine following a metronomic schedule that involves the regular administration of cytotoxic drugs at doses lower than standard treatment. In vitro results showed that human endothelial cells are more sensitive to gemcitabine (IC50 3 nmol/L) than pancreatic tumor cells (IC50 20 nmol/L). For in vivo studies, we used an orthotopic implantation model of human pancreatic carcinoma in nude mice. Gemcitabine was administered i.p. following a low-dose schedule (1 mg/kg/d for a month) and compared with the conventional schedule (100 mg/kg days 0, 3, 6, and 9 postimplantation). Metronomic treatment effect on established tumor was equivalent to standard administration. The measure of CD31 endothelial marked area allowed us to show an in vivo antiangiogenic effect of this drug that was further enhanced by using metronomic administration. This effect correlated with an induction of thrombospondin-1, a natural inhibitor of angiogenesis. Our results allow us to hypothesize that, in addition to a direct antiproliferative or cytotoxic antiendothelial cell effect, a secondary effect involving thrombospondin-1 induction might provide an explanation for the specificity of the effects of metronomic gemcitabine treatment.
Note: Versió postprint del document publicat a:
It is part of: Molecular Cancer Therapeutics, 2008, vol. 7, num. 3, p. 638-647
Related resource:
ISSN: 1535-7163
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Fisiològiques)

Files in This Item:
File Description SizeFormat 
558692.pdf79 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.